By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Lipocine Inc. 

675 Arapeen Drive
Suite 202
Salt Lake City  Utah  84108  U.S.A.
Phone: 801-994-7383 Fax:


Company News
Lipocine (LPCN) Completes Enrollment In The LPCN 1021 Fixed Dose Clinical Trials 4/24/2017 10:15:38 AM
Lipocine (LPCN) Announces Financial And Operational Results For The Full Year Of 2016 3/7/2017 11:13:54 AM
Lipocine (LPCN) Announces The Promotion Of Gregory Bass To Chief Commercial Officer 2/15/2017 8:11:38 AM
Lipocine (LPCN) Receives FDA Guidance On The Phase III Program For LPCN 1107, An Oral Alternative For The Prevention Of Preterm Birth 1/9/2017 7:16:33 AM
Lipocine (LPCN) To Initiate Dosing Validation Study For LPCN 1021, Oral Testosterone Replacement Product Candidate 12/5/2016 8:27:40 AM
Lipocine (LPCN) Announces Financial And Operational Results For The Third Quarter Of 2016 11/8/2016 7:50:36 AM
Lipocine (LPCN) Announces Issuance Of US Patent 9,480,690 11/7/2016 8:11:52 AM
Lipocine (LPCN) Completes Post Action Meeting With FDA For LPCN 1021 New Drug Application 10/17/2016 7:13:25 AM
Clarus Therapeutics Provides Update On Patent Infringement Lawsuit Against Lipocine (LPCN)'s Oral Product For Testosterone Replacement Therapy 10/13/2016 8:15:26 AM
Lipocine (LPCN) Wins Dismissal Of Patent Infringement Lawsuit Related To LPCN 1021 10/10/2016 9:02:53 AM